Did you receive a flu vaccination this season?
This season's vaccine does not match the circulating H3N2 strain.
H3N2 mutated into subclade K after the 2025–2026 flu vaccine was manufactured and distributed. The vaccine administered to over 200 million Americans was formulated for a strain that no longer circulates.
This is an inherent limitation of influenza vaccine production. Formulations are finalized 6–8 months before distribution. Late-season antigenic drift cannot be accounted for.
87% mismatch — CDC Surveillance 2026Have you experienced any of the following in the past 90 days?
Select all that apply
Which high-exposure environments are part of your weekly routine?
Select all that apply
How many times have you been ill in the past 12 months?
All respiratory viruses enter the body through the nasal passage.
Influenza A (H3N2), RSV, and SARS-CoV-2 share the same primary infection route: the nasal epithelium — the mucosal tissue lining the interior of the nose.
The immune system activates after viral entry has occurred. Current preventive measures — vaccination, hand hygiene, oral supplements — do not provide direct protection at the nasal entry point.
A growing number of frontline healthcare workers have adopted nasal antiseptic protocols to neutralize pathogens before systemic infection can begin.
Nasal passage = primary viral entry pointWhich preventive measures do you currently use?
Select all that apply
None of the measures listed above protect the nasal entry point.
Vitamin supplements support the systemic immune response after infection has already occurred. Hand hygiene addresses fomite-based transmission. This season's vaccine was formulated for a strain that has since undergone antigenic drift.
Zero of the four most common preventive measures provide direct protection at the nasal epithelium — the primary site of H3N2 viral entry.
0 of 4 defenses address the nasal entry pointHow would you rate your concern about contracting H3N2 this season?
Do you have regular contact with immunocompromised individuals, elderly family, or young children?
Are you currently taking daily prescription medications?
Antihypertensives, statins, metformin, anticoagulants, etc.
Which age group applies to you?
Age is a primary variable in H3N2 risk stratification.
If a clinically validated, 10-second daily nasal hygiene protocol could reduce your exposure risk — would you adopt it?
Generating your risk assessment…
Assessment: Your nasal passages are currently unprotected against the circulating H3N2 strain.
Your responses indicate multiple compounding risk factors — including exposure frequency, reliance on preventive measures that do not address the nasal entry point, and this season's 87% vaccine mismatch rate.
Recommended: Nasal Antiseptic Protocol
A growing number of ER physicians and frontline healthcare workers use povidone-iodine nasal spray — the same hospital-grade antiseptic used in surgical preparation — applied directly to the nasal passages. Clinical data indicates it neutralizes 99% of respiratory pathogens within 90 seconds at the point of entry. No known drug interactions. No rebound effect. 10 seconds, twice daily.